Methods
We undertook a retrospective analysis of all new patients presenting to our HIV service between 2002 and 2007. Patient demographics including country of origin, VZV IgG status and CD4 count were collected. The household membership of all non-VZV immune patients was attempted to be ascertained by telephone.
Summary of results
594 HIV-positive patients were tested for Varicella IgG. 544 (91.6%) of these were VZV IgG positive. Of the 50 that were not immune, 42 had CD4 >200. 218 (36.8%) of the total were from SSA. Of this group, 33 (15%) were non-immune compared with only 15 (4%) of the European cohort. Non-immune patients with CD4>200 were contacted by telephone and offered vaccination.This is currently ongoing. The SSA patients were cautious in disclosing their living circumstances. Those non-immune patients with CD4<200 were advised to seek vaccination for their household contacts.
Conclusion
Primary varicella infection in the HIV-positive population poses a credible threat. Our review of VZV immune status in a cohort of HIV-positive patients identifies the SSA population is a particular "at risk" group. Current guidelines advise that non-immune patients with CD4 counts >200 can be vaccinated, whereas those with CD4 counts <200 should have their household contacts vaccinated. The non-immune patients who had CD4>200 were offered vaccination. Educating patients re household contact vaccination is difficult in this population. Inclusion of VZV in the universal childhood vaccination schedule would help in this regard. We are presently assessing all patients with regard to requirement for VZV vaccination, with particular focus on those who migrated from SSA prior to 2002.
